Abstract
Osteoporotic hip fractures (HFs) in the elderly are a pertinent issue in healthcare, particularly in developed countries such as Australia. Estimating prognosis following admission remains a key challenge. Current predictive tools require numerous patient input features including those unavailable early in admission. Moreover, attempts to explain machine learning [ML]-based predictions are lacking. We developed 7 ML prognostication models to predict in-hospital mortality following minimal trauma HF in those aged ≥ 65 years of age, requiring only sociodemographic and comorbidity data as input. Hyperparameter tuning was performed via fractional factorial design of experiments combined with grid search; models were evaluated with 5-fold cross-validation and area under the receiver operating characteristic curve (AUROC). For explainability, ML models were directly interpreted as well as analyzed with SHAP values. Top performing models were random forests, naïve Bayes [NB], extreme gradient boosting, and logistic regression (AUROCs ranging 0.682 – 0.696, p>0.05). Interpretation of models found the most important features were chronic kidney disease, cardiovascular comorbidities and markers of bone metabolism; NB also offers direct intuitive interpretation. Overall, we conclude that NB has much potential as an algorithm, due to its simplicity and interpretability whilst maintaining competitive predictive performance.
Author Summary Osteoporotic hip fractures are a critical health issue in developed countries. Preventative measures have ameliorated this issue somewhat, but the problem is expected to remain in main due to the aging population. Moreover, the mortality rate of patients in-hospital remains unacceptably high, with estimates ranging from 5-10%. Thus, a risk stratification tool would play a critical in optimizing care by facilitating the identification of the susceptible elderly in the community for prevention measures and the prioritisation of such patients early during their hospital admission. Unfortunately, such a tool has thus far remained elusive, despite forays into relatively exotic algorithms in machine learning. There are three major drawbacks (1) most tools all rely on information typically unavailable in the community and early during admission (for example, intra-operative data), limiting their potential use in practice, (2) few studies compare their trained models with other potential algorithms and (3) machine learning models are commonly cited as being ‘black boxes’ and uninterpretable. Here we show that a Naïve Bayes model, trained using only sociodemographic and comorbidity data of patients, performs on par with the more popular methods lauded in literature. The model is interpretable through direct analysis; the comorbidities of chronic kidney disease, cardiovascular, and bone metabolism were identified as being important features contributing to the likelihood of deaths. We also showcase an algorithm-agnostic approach to machine learning model interpretation. Our study shows the potential for Naïve Bayes in predicting elderly patients at risk of death during an admission for hip fracture.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the Declaration of Helsinki (1964) and the Council for International Organisations of Medical Sciences International Ethic Guidelines and approved by the Australian Capital Territory Human Research Ethics Committee (reference number: 2023.LRE.00063). Because the analysis was based on a digital anonymized database, the patients’ written informed consent was waived.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The raw data supporting the conclusions of this article will be made available by the authors on request, without undue reservation.
